MENU

Michael Hall, MD, MS, named Chair of the Department of Clinical Genetics at Fox Chase Cancer Center

May 22, 2019

As both an oncologist and a clinical cancer geneticist, Dr. Hall focuses his research and clinical work on cancers of the gastrointestinal tract, with experience in risk assessment for gastrointestinal, endocrine, and genitourinary cancers.As both an oncologist and a clinical cancer geneticist, Dr. Hall focuses his research and clinical work on cancers of the gastrointestinal tract, with experience in risk assessment for gastrointestinal, endocrine, and genitourinary cancers.PHILADELPHIA (May 22, 2019) – Michael Hall, MD, MS, has been named chair of the Department of Clinical Genetics at Fox Chase Cancer Center.

An Associate Professor in the Department of Clinical Genetics, Dr. Hall will continue to serve in his other roles at Fox Chase, including director of Gastrointestinal Risk Assessment; and NCCN, Genetic Colorectal/Colorectal Cancer Screening Panel member.

“Dr. Hall has served our institution in an outstanding fashion for a number of years. Recognized among America’s Top Doctors by Castle Connolly and our region’s Top Doctors by Philadelphia magazine, he is well-regarded by professional peers and patients alike,” said Richard I. Fisher, MD, president & CEO of Fox Chase Cancer Center.

As both an oncologist and a clinical cancer geneticist, Dr. Hall brings a valuable combination of experience to the department. He focuses his research and clinical work on cancers of the gastrointestinal tract with particular interest in colorectal, pancreatic, and small bowel cancers. In addition, he has specialized expertise in risk assessment for gastrointestinal, endocrine, and genitourinary cancers. In his practice, he sees a variety of patients, including young people who tend to have hereditary cancers, and consistently approaches each case with a great appreciation for the unique diagnosis and needs of the patient.

As chair, Dr. Hall will lead the department, building on the legacy of his predecessor Mary Daly, MD, founding director of Fox Chase Cancer Center’s Risk Assessment Program, and further bolstering the strength of Fox Chase’s clinical and research programs, cultivating new and innovative initiatives and promoting the development of the faculty and staff.

       

The Hospital of Fox Chase Cancer Center and its affiliates (collectively “Fox Chase Cancer Center”), a member of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence five consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.
For more information, call 1-888-FOX CHASE or (1-888-369-2427).

Connect with Fox Chase